Cargando…

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population

OBJECTIVE: The aim of the study was to assess the effectiveness of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients treated in MS centres in Poland. METHODS: Demographic and clinical data of all Polish RRMS patients receiving DMTs were prospectively collec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapica-Topczewska, Katarzyna, Tarasiuk, Joanna, Collin, Francois, Brola, Waldemar, Chorąży, Monika, Czarnowska, Agata, Kwaśniewski, Mirosław, Bartosik-Psujek, Halina, Adamczyk-Sowa, Monika, Kochanowicz, Jan, Kułakowska, Alina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812766/ https://www.ncbi.nlm.nih.gov/pubmed/31647829 http://dx.doi.org/10.1371/journal.pone.0223863

Ejemplares similares

Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review
por: Tarasiuk, Joanna, et al.
Publicado: (2022)

Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2021)

Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination
por: Czarnowska, Agata, et al.
Publicado: (2023)

Severe tick-borne encephalitis in a patient recovered from COVID 19
por: Czarnowska, Agata, et al.
Publicado: (2022)

Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
por: Bartosik-Psujek, Halina, et al.
Publicado: (2023)

The Big Five Personality Traits and Positive Orientation in Polish Adults with Multiple Sclerosis: The Role of Meaning in Life
por: Szcześniak, Małgorzata, et al.
Publicado: (2022)

Month of birth and level of insolation as risk factors for multiple sclerosis in Poland
por: Dobrakowski, Paweł, et al.
Publicado: (2017)

Disturbed Ratios between Essential and Toxic Trace Elements as Potential Biomarkers of Acute Ischemic Stroke
por: Mirończuk, Anna, et al.
Publicado: (2023)

Variants of Novel Immunomodulatory Fc Receptor Like 5 Gene Are Associated With Multiple Sclerosis Susceptibility in the Polish Population
por: Chorazy, Monika, et al.
Publicado: (2021)

The most important psychological and psychosocial needs of Polish multiple sclerosis patients and their significant others
por: Potemkowski, Andrzej, et al.
Publicado: (2017)

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
por: Czarnowska, Agata, et al.
Publicado: (2021)

Some Common SNPs of the T-Cell Homeostasis-Related Genes Are Associated with Multiple Sclerosis, but Not with the Clinical Manifestations of the Disease, in the Polish Population
por: Chorąży, Monika, et al.
Publicado: (2020)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

Hyperglycemia and diabetes have different impacts on outcome of ischemic and hemorrhagic stroke
por: Snarska, Katarzyna K., et al.
Publicado: (2016)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Carpal tunnel syndrome conservative treatment: a literature review
por: Wielemborek, Przemysław T., et al.
Publicado: (2022)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Internet Usage by Polish Patients With Multiple Sclerosis: A Multicenter Questionnaire Study
por: Potemkowski, Andrzej, et al.
Publicado: (2019)

Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
por: Czarnowska, Agata, et al.
Publicado: (2022)

Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland
por: Czarnowska, Agata, et al.
Publicado: (2022)

Selenium, Copper, Zinc Concentrations and Cu/Zn, Cu/Se Molar Ratios in the Serum of Patients with Acute Ischemic Stroke in Northeastern Poland—A New Insight into Stroke Pathophysiology
por: Mirończuk, Anna, et al.
Publicado: (2021)

The FOXP3 rs3761547 Gene Polymorphism in Multiple Sclerosis as a Male-Specific Risk Factor
por: Wawrusiewicz-Kurylonek, Natalia, et al.
Publicado: (2018)

Case report: Variants in the ERCC4 gene as a rare cause of cerebellar ataxia with chorea
por: Kulikowska, Joanna, et al.
Publicado: (2023)

Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients – preliminary study
por: Rudnicka, Julia, et al.
Publicado: (2015)

Kappa Free Light Chains and IgG Combined in a Novel Algorithm for the Detection of Multiple Sclerosis
por: Gudowska-Sawczuk, Monika, et al.
Publicado: (2020)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
por: Lefort, M., et al.
Publicado: (2022)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
por: Braune, Stefan, et al.
Publicado: (2018)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
por: Kemmerer, C. L., et al.
Publicado: (2020)

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
por: Sanchez-de la Rosa, Rainel, et al.
Publicado: (2013)

The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland
por: Brola, Waldemar, et al.
Publicado: (2022)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Prevalence and incidence of multiple sclerosis in central Poland, 2010–2014
por: Brola, Waldemar, et al.
Publicado: (2016)

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9qhqllq5lvfb5f7q8g7sdbp0r4